Related Experiment Video

Updated: Nov 12, 2025

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

5.4K

Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5%

Wayne Kaesemeyer1, Tatsiana Suvorava2

  • 1Augusta Hypertension PC, 108 Tharrington Drive, Chapel Hill, NC, USA. kaehtn007@yahoo.com.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|March 22, 2021
PubMed

Insights

This article presents a new treatment for acute decompensated heart failure (ADHF) in COVID-19 patients. It uses a novel intravenous nitroglycerin formulation with glutathione to speed recovery and lower complication risks.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Coronavirus disease 2019 (COVID-19) can lead to acute decompensated heart failure (ADHF).
  • Standard treatments for ADHF may have limitations in COVID-19 patients.

Purpose of the Study:

  • To introduce a novel therapeutic approach for ADHF in COVID-19 patients.
  • To describe a new formulation of intravenous nitroglycerin using 5% glutathione.

Main Methods:

  • This is a current opinion article, outlining a proposed treatment strategy.
  • The proposed method involves the novel use of intravenous nitroglycerin reformulated in 5% glutathione.

Main Results:

  • The novel formulation is hypothesized to improve the resolution rate of ADHF.
  • It is also expected to reduce the risk of heart failure complications in COVID-19 patients.

Conclusions:

  • This novel approach offers a potential advancement in managing ADHF in the context of COVID-19.
  • Further investigation and clinical trials are warranted to validate the efficacy and safety of this new formulation.

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.1K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.5K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
75
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
94
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
917
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
86
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
418
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
113